The Therapeutic Potential of Adipose-Derived Mesenchymal Stem Cell Secretome in Osteoarthritis: A Comprehensive Study
Authors:
- Elsa González-CuberoEGElsa González-Cubero
- Maria Luisa González-FernándezMGMaria Luisa González-Fernández
- Marta Esteban-BlancoMEMarta Esteban-Blanco
- Saúl Pérez-CastrilloSPSaúl Pérez-Castrillo
- Esther Pérez-FernándezEPEsther Pérez-Fernández
- Nicolás NavasaNNNicolás Navasa
- Ana M. AransayAAAna M. Aransay
- Juan AnguitaJuan Anguita
- Vega Villar-SuárezVVVega Villar-Suárez
Open Access
- 20 October 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (20) , 11287
Abstract
Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage degradation and inflammation. This study investigates the therapeutic potential of secretome derived from adipose tissue mesenchymal stem cells (ASCs) in mitigating inflammation and promoting cartilage repair in an in vitro model of OA. Our in vitro model comprised chondrocytes inflamed with TNF. To assess the therapeutic potential of secretome, inflamed chondrocytes were treated with it and concentrations of pro-inflammatory cytokines, metalloproteinases (MMPs) and extracellular matrix markers were measured. In addition, secretome-treated chondrocytes were subject to a microarray analysis to determine which genes were upregulated and which were downregulated. Treating TNF-inflamed chondrocytes with secretome in vitro inhibits the NF-κB pathway, thereby mediating anti-inflammatory and anti-catabolic effects. Additional protective effects of secretome on cartilage are revealed in the inhibition of hypertrophy markers such as RUNX2 and COL10A1, increased production of COL2A1 and ACAN and upregulation of SOX9. These findings suggest that ASC-derived secretome can effectively reduce inflammation, promote cartilage repair, and maintain chondrocyte phenotype. This study highlights the potential of ASC-derived secretome as a novel, non-cell-based therapeutic approach for OA, offering a promising alternative to current treatments by targeting inflammation and cartilage repair mechanisms.Keywords
All Related Versions
Funding Information
- MCIN/AEI/10.13039/501100011033 (CEX2021-001136-S)
- Regional Government of Castile and Leon (Spain) (CEX2021-001136-S)
This publication has 50 references indexed in Scilit:
- Uncovering the secretes of mesenchymal stem cellsBiochimie, 2013
- The NF-κB signalling pathway in osteoarthritisThe International Journal of Biochemistry & Cell Biology, 2013
- Methodology, Biology and Clinical Applications of Human Mesenchymal Stem Cells2012
- Concise Review: Induced Pluripotent Stem Cell‐Derived Mesenchymal Stem Cells: Progress Toward Safe Clinical ProductsStem Cells, 2011
- The pro- and anti-inflammatory properties of the cytokine interleukin-6Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Cytokine‐induced increases in ADAMTS‐4 messenger RNA expression do not lead to increased aggrecanase activity in ADAMTS‐5–deficient miceArthritis & Rheumatism, 2010
- Understanding the role of tissue degrading enzymes and their inhibitors in development and diseaseBest Practice & Research Clinical Rheumatology, 2006
- Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: Associations with degenerative changesArthritis & Rheumatism, 2001
- Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-jun N-terminal kinase, and nuclear factor κB: Differential regulation of collagenase 1 and collagenase 3Arthritis & Rheumatism, 2000
- The role of nitric oxide in inflammation and immunityArthritis & Rheumatism, 1998